What is SynerFuse?
SynerFuse is developing an integrated solution for chronic low back and leg pain through its e-TLIF procedure, which incorporates Ultra Low Energy (ULE) therapy. The company's focus is on spinal fusion patients who suffer from chronic pain unresponsive to opioids. With a substantial market of over 90 million individuals in the United States affected by chronic low back pain, SynerFuse aims to enhance patient outcomes and decrease reliance on opioid prescriptions through its innovative medical technology.
How much funding has SynerFuse raised?
SynerFuse has raised a total of $110K across 1 funding round:
Debt
$110K
Debt (2021): $110K with participation from PPP
Key Investors in SynerFuse
PPP
Public-Private Partnership
What's next for SynerFuse?
The large-scale, late-stage funding context suggests SynerFuse is poised for significant scaling and market penetration. This strategic investment will likely fuel further clinical validation, expansion of manufacturing capabilities, and broader commercialization efforts. The company's trajectory indicates a strong push towards establishing its e-TLIF procedure as a leading alternative for patients suffering from chronic spinal pain, potentially reshaping treatment paradigms and reducing the societal burden of opioid dependence.
See full SynerFuse company page
